Esperion - Raising Prospects In Lowering Cholesterol
July 12, 2020 at 15:04 PM EDT
Esperion Therapeutics just announced a pooled efficacy analysis from the four Phase III clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering medicine.
